Current Problems in Cancer 1991: Vol 15 Index

11 Pages·1991·1.7 MB·English

1991 INDEX
A as tumor markers, Nov/Dec. 323-
Adenocarcinoma: of lung, Mar/Apr. 324
Breast cancer, early stage, July/Aug.
85-86
Alkaline phosphatase: placental, as 161—232
abstract, July/Aug. 161-162
tumor marker, Nov/Dec.
chemotherapy of, adjuvant, July/
330-331
Aug. 183-200
Allele losses: at multiple sites in
lung cancer, Mar/Apr. 71 drug regimen, optimal, July/
Aug. 191-192
Alpha-fetoprotein
elevation in various diseases, duration of, optimal, July/Aug.
Nov/Dec. 314 193—194
in germ cell tumors, Nov/Dec. 316 IBSCG Trial, July/Aug. 187
screening results, Nov/Dec. 315 Intergroup Trial, July/Aug. 187-
as tumor marker, Nov/Dec. 313- 188
Milan Trial, July/Aug. 186-187
317
Antigen(s) NSABP B-13 in, July/Aug. 188
cancer, mucinous-like, as tumor regimens for, selection of, July
Aug. 194-195
marker, Nov/Dec. 323-324
carcinoembryonic (see Carcino- single-agent vs. combination,
embryonic antigen) July/Aug. 192-193
carcinoma, squamous cell, as tu- studies of, July/Aug. 183-188
mor marker, Nov/Dec. 318 toxicity of, July/Aug. 198-200
trials of, July/Aug. 184-185
Lewis, and mucin-glycoprotein
epitopes, Nov/Dec. 321 chemotherapy, dose intensity
July/Aug. 188— 190
prostate specific, as tumor
DNA ploidy and, July/Aug. 176-
marker, Nov/Dec. 318-320
tissue polypeptide, as tumor 178
endocrine treatment, July/Aug.
marker, Nov/Dec. 317
Asbestos: and lung cancer, Mar. 200-214
historical perspective July/Aug.
Apr. 68—69
Assays: of hormone receptor, com- 200—202
new therapies, July/Aug. 213-
parison of, July/Aug. 172
214
genetic alterations in, July/Aug.
178-181
B-cell lymphoma: after marrow growth factor receptors in, July
transplant, Jan/Feb. 40-41 Aug. 178-181
Beta-2-microglobulin: as tumor hormone
marker, Nov/Dec. 335-338 receptor status, determination
Biopsy: percutaneous fine-needle and significance, July/Aug.
aspiration, in lung cancer, 170-174
Mar/Apr. 82—83 replacement, regulation and
Bone marrow (see Marrow) pregnancy in, July/Aug. 174-
Breast cancer-associated mucinous 176
glycoproteins, Nov/Dec. 323- medical management, July/Aug.
324 161—232
Curr Probl Cancer, November/December 1991
Breast cancer (cont.) breast (see Breast cancer)
multimodality treatment, se- colon, CEA elevation in, Nov/Dec.
quencing of, July/Aug. 195- 308
198 esophageal (see Esophagus, can-
oncogenes in, July/Aug. 178-181 cer)
posttherapy evaluations, July/Aug. gastric (see Gastric cancer)
214-215 gastrointestinal tract (see Gastro-
prognostic factors, July/Aug. 162- intestinal tract cancer)
183 hematological, marrow transplant
application of, July/Aug. 181-183 in, Jan/Feb. 19-33
histology in, July/Aug. 169-170 lung (see Lung cancer)
metastases extent in, July/Aug ovarian, marrow transplant in,
166-169 Jan/Feb. 36
overview of, July/Aug. 182 pancreas, CA 19-9 in, Nov/Dec.
proliferative fraction in, July 325
Aug. 176-178 testicular, marrow transplant in,
recurrence in, local, July/Aug Jan/Feb. 34-35
163— 165 Carboplatin
size of tumor in, July/Aug. 166—- in esophageal cancer, Sept/Oct.
169 259
tamoxifen in, July/Aug. 202-207 in marrow transplant, Jan/Feb. 13
210-211 Carcinoembryonic antigen
trials, July/Aug. 203 concentrations in sera, Nov/Dec
Breast cancer: marrow transplant 306
in, Jan/Feb. 35-36 elevated
Bronchioloalveolar carcinoma in colon cancer, Nov/Dec. 308
characteristics of, Mar/Apr conditions associated with,
76-77 Nov/Dec. 305
pathology, Mar/Apr. 85-86 studies using, summary of, Nov.
Bronchoscopy: fiberoptic, in lung Dec. 310-311
cancer detection, Mar/Apr as tumor marker, Nov/Dec. 304-
81-82 313
Carcinogens: and lung cancer, Mar.
Apr. 68-69
Cc
Carcinoma
CA 15-3: as tumor marker, Nov Dec bronchioloalveolar
322 characteristics, Mar/Apr. 76—77
CA 19-9: as tumor marker, Nov Dec pathology, Mar/Apr. 85-86
324-326 esophagus (see Esophagus, carci-
CA 50: as tumor marker, Nov/Dec noma)
324-326 lung (see Lung carcinoma)
CA 125: as tumor marker, Nov/Dec squamous cell, antigen as tumor
327-328 marker, Nov/Dec. 318
CA 195: as tumor marker, Nov/Dec Catecholamines: as tumor marker,
326-327 Nov/Dec. 333-334
Calcitonin: as tumor marker, Nov Cellis)
Dec. 331 germ cell tumors, Nov/Dec. 316
Cance! stem (see Stem cells)
antigen, mucinous-like, as tumor Cerebral metastasis: solitary, in lung
marker, Nov/Dec. 323-324 cancer, May/June 117
Curr Probl Cancer, November/December 1991
Chemohormonal treatment: in Drugs: cytotoxic, in marrow trans-
breast cancer, July/Aug. 207- plant, Jan/Feb. 12-14
210 DuPAN-2: as tumor marker, Nov.
Chemotherapy Dec. 326
in breast cancer (see Breast can- Dysphagia: in esophageal carci-
cer, early stage, chemotherapy) noma, palliative techniques
of esophageal cancer (see under for, Sept/Oct. 267-268
Esophagus, cancer)
of esophageal carcinoma (see un-
E
der Esophagus, carcinoma)
of gastric cancer (see under Gas- EAP: in gastric cancer, Sept/Oct.
tric cancer) 280
in gastrointestinal tract cancer, Epstein-Barr virus B-cell lymphoma
upper, postoperative, Sept. after marrow transplant, Jan.
Oct. 250 Feb. 40-41
in lung cancer (see Lung cancer, Endocrine
non-small cell, chemother- dysfunction after marrow trans-
apy of) plant, Jan/Feb. 44
in marrow transplant (see Marrow therapy in breast cancer (see
transplant, chemotherapy) Breast cancer, early stage,
Chest symptoms: in lung cancer, endocrine treatment)
Mar/Apr. 75—77 Enolase: neuron specific, as tumor
Chromosome changes: in lung can- marker, Nov/Dec. 329
cer, Mar/Apr. 71 Enzyme markers: in oncology, Nov.
Cisplatin-based regimens: in lung Dec. 328-331
cancer, May/June 130-131 Esophagus, cance!
Colon: cancer, CEA elevation in carboplatin in, Sept/Oct. 259
Nov/Dec. 308 chemotherapy
Cranial radiotherapy: prophylactic, combination, Sept/Oct. 258
in lung cancer, May/June 126 single agent, Sept/Oct. 254- 2?
Cryopreservation definition of TNM, Sept/Oct. 2 4:
general principles, Jan/Feb. 10-11 failure pattern, autopsy data,
quality of, Jan/Feb. 10 Sept/Oct. 246
Cyclophosphamide: in marrow metastases, sites of, Sept/Oct. 246
transplant, Jan/Feb. 12-13 Esophagus, carcinoma, Sept/Oct.
Cystitis: hemorrhagic, after marrow 252-268
transplant, Jan/Feb. 44 chemotherapy, Sept/Oct. 2 253-260
Cytologic smears: of sputum, in combination, Sept/Oct. 2 257-260
lung cancer detection, Mar. drug regimen choice, Sept/Oct.
Apr. 80 261
Cytomegalovirus: after marrow with radiotherapy, Sept/Oct.
transplant, Jan/Feb. 39 263—266
Cytotoxic drugs: in marrow trans- surgery after, Sept/Oct. 261-
plant, Jan/Feb. 12-14 263
combined modality therapy,
Sept/Oct. 261
D
toxicities with, additive, Sept.
Diet: and lung cancer, Mar/Apr. 69 Oct. 261
DNA ploidy: in breast cancer, July dysphagia in, palliative tech-
Aug. 176-178 niques for, Sept/Oct. 267—268
Curr Probl Cancer, November/December 1991 353
Esophagus (cont.) adjuvant therapy
interferon with fluorouracil in, choosing appropriate patient,
Sept/Oct. 260 Sept/Oct. 249-250
Intergroup Trial, Sept/Oct. 266- postoperative, timing of, Sept/
268 Oct. 252
neoadjuvant therapy, Sept/Oct. rationale for, Sept/Oct. 248-252
260-268 site of primary, Sept/Oct. 248-
radiotherapy of, Sept/Oct. 253 249
with chemotherapy, Sept/Oct chemotherapy, postoperative,
263— 266 Sept/Oct. 250
preoperative, Sept/Oct. 260-261 epidemiology, changing, 240-241
response assessment, Sept/Oct failure pattern, Sept/Oct. 245-248
254 prognostic variables, Sept/Oct.
surgery, Sept/Oct. 252-253 243-245
with preoperative chemother- screening, Sept/Oct. 241-242
apy, Sept/Oct. 261-263 staging, Sept/Oct. 242-243
treatment, Sept/Oct. 252-268 surgical procedure employed,
type of, Sept/Oct. 250-252
FP survival by stage, Sept/Oct. 251
treatment, Sept/Oct. 239-293
FAMTX: in gastric cancer, Sept/Oct. Gene
281 p53, abnormalities in lung cancer,
a-Fetoprotein (see Alpha- Mar/Apr. 72
fetoprotein) rb, in lung cancer, Mar/Apr. 72
Fiberoptic bronchoscopy: in lung Genetic
cancer detection, Mar/Apr alterations in breast cancer, July
81-82 Aug. 178-181
Fluorouracil: with interferon in lesions in lung cancer, Mar/Apr.
esophageal carcinoma, Sept.
69-74
Oct. 260 Germ cell tumors, Nov/Dec. 316
Glycoprotein(s)
G -mucin epitopes and Lewis anti-
gens, Nov/Dec. 321
Gastric cancer, Sept/Oct. 268—282 mucinous, as tumor marker,Nov.
adjuvant therapy, Sept/Oct. 268- Dec. 320-328
273 tumor markers, Nov/Dec. 304-
advanced, Sept/Oct. 273-282 320
chemotherapy, combination, Gonadotropin, beta-human chori-
Sept/Oct. 275-282 onic, Nov/Dec. 313-317
chemotherapy of, single agent, in germ cell tumors, Nov/Dec
Sept/Oct. 273-275
316
chemotherapy, intraperitoneal, Graft: hematopoietic stem cell, in
Sept/Oct. 271-273 marrow transplant, Jan/Feb. 9
definition of TNM, Sept/Oct. 244 Growth regulatory system: in lung
EAP in, Sept/Oct. 280 cancer, Mar/Apr. 72-73
FAMTX in, Sept/Oct. 281
metastases, sites of, Sept/Oct. 247
H
Gastrointestinal tract cancer, upper,
Sept/Oct. 239-293 Hematological cancer: marrow
abstract, Sept/Oct. 239 transplant in, Jan/Feb. 19-33
354 Curr Probl Cancer, November/December 1991
Hematopoietic Leukemia: marrow transplant in,
reconstitution, methods, Jan/Feb. 7 Jan/Feb. 28-32
stem cell (see Marrow transplant, Lewis antigens: and mucin-
hematopoietic stem cell) glycoprotein epitopes, Nov.
Hemorrhagic cystitis: after marrow Dec. 321
transplant, Jan/Feb. 44 Liver toxicity: in marrow transplant,
Herpes simplex: after marrow trans- Jan/Feb. 41-43
plant, Jan/Feb. 38-39 Lung
Hodgkin's disease adenocarcinoma, Mar/Apr. 85-86
marrow transplant in, Jan/Feb cancer (see below
25-28 carcinoma
results, Jan/Feb. 23, 28 large cell, Mar/Apr. 86
relapsed and refractory, condi- squamous cell, Mar/Apr. 85
tioning regimens for, Jan. stem cells in lung cancer, Mar.
Feb. 26 Apr. 84—85
Hormone(s) toxicity and marrow transplant,
in breast cancer (see Breast can- Jan/Feb. 41
cer, early stage, hormone in) Lung cancer, non-small cell, Mar.
chemohormonal treatment in Apr. 65—104, May/June 109-
breast cancer, July/Aug. 207—- 154
210 abstract, Mar/Apr. 65-67
receptor assays, comparison of, allele losses at multiple sites,
July/Aug. 172 Mar/Apr. 71
therapy in breast cancer, toxicity asbestos and, Mar/Apr. 68—69
of, July/Aug. 211-213 biopsy in, percutaneous fine-
as tumor markers, Nov/Dec. 331- needle aspiration, Mar/Apr
334 82-83
bronchoscopy in, fiberoptic, Mar.
I Apr. 81-82
carcinogens in, Mar/Apr. 68-69
ifosfamide: in marrow transplant,
chemotherapy, May/June 126,
Jan/Feb. 13
127-142
Immune system molecules: as tu-
administration principles, May
mor markers, Nov/Dec. 334-
June 128-134
338 combination, May/June 129-134
Immunoglobulins: as tumor mark-
combination, cyclic alternating
ers, Nov/Dec. 334-335 May/June 132
Interferon: with fluorouracil in
dose-response relationships,
esophageal carcinoma, Sept.
May/June 131-132
Oct. 260 duration of, May/June 132-133
Irradiation (see Radiotherapy)
morbidity and mortality after,
May/June 134—135
kK perspective on, May/June 141-
Kaplan-Meier survival curves: in 142 .
mveloma, Nov/Dec. 336 preoperative, May/June 138-—
: 139, 140
L prognostic factors with, May
June 133-134
Lactic acid dehydrogenase: as tu- with radiotherapy, May/June
mor marker, Nov/Dec. 330 137-138
Curr Probl Cancer, November/December 1991
Lung cancer (cont.) neuroendocrine features, Mar.
response assessment, May/June Apr. 86
128 nicotine in, Mar/Apr. 72—73
results, May/June 135-141 occult
selection of patients, May/June identification of, Mar/Apr
127—128 80-81
single-agent, May/June 128-129 resection results in, May/June
single agent, efficacy of, May 115
June 130 oncogenes in
with surgery, May/June 139-141 dominant, Mar/Apr. 70-71
survival and response in, May recessive, Mar/Apr. 71—74
June 133 operability determination, May
chest symptoms in, Mar/Apr June 112-113
opioids in, Mar/Apr. 72—73
chromosomal changes in, Mat paraneoplastic syndromes in
\pr. 71 Mar/Apr. 77
cisplatin-based regimens in, effi pathogenesis
cacy, May/June 130-131 molecular, Mar/Apr. 69-74
clinical features, Mar/Apr. 74—78 stages in, Mar/Apr. 84—85
detection, early, Mar/Apr. 78 pathology, Mar/Apr. 83-86
with biochemical markers pericardial effusion in, Mar/Apr
Mar/Apr. 80 76
detection, immunohistochemical p53 gene abnormalities in, Mar
from sputum cytologic Apr. 72
smears, Mar/Apr. 80 pleural effusion in, malignant
diagnosis, pathologic, Mar/Apr Mar/Apr. 76
81-83 predisposition to, inherited, Mar
diet and, Mar/Apr. 69 Apr. 73-74
etiology, Mar/Apr. 67-74 prognostic factors, Mar/Apr
genetic lesions in, Mar/Apr 86-92
69-74 radiotherapy in, May/June 118-
growth regulatory system in —9/°
Mar/Apr. 72-73 adjuvant, May/June 125-127
histologic types, frequency of with chemotherapy, May/June
Mar/Apr. 84 137-138
histopathologic events in, early combination, contradictory ef-
Mar/Apr. 84—85 fects of, May/June 134
investigational approaches to tu- cranial, prophylactic, May/June
mor reduction, May/June 126
142-143 definitive, May/June 118-125
metastases in definitive, dose, May/June 120-
cerebral solitary, May/June 117 121
outside thorax, Mar/Apr. 77 definitive, selection of patients
microscopic tumor at bronchial May/June 119
margin, resection results definitive, survival effects of
May/June 117 May/June 123-124
mutations in definitive, treatment volume
number and timing, Mar/Apr May/June 119-120
73 failure patterns, May/June 124-
ras, Mar/Apr. 70 125
Curr Probl Cancer, November/December 1991
fractionation, May/June 120- survival by stage, Mar/Apr. 83
122 treatment, May/June 109-154
morbidity of, May/June 122 abstract, May/June 109-111
palliative, May/June 126-127 palliative, May/June 143-144
postoperative, May/June 125 vena cava syndrome in, superior,
preoperative, May/June 125 Mar/Apr. 76
results, May/June 122-123 Lung cancer: small cell, marrow
in stage IV, May/June 126 transplant in, Jan/Feb. 33
survival with, May/June 122-— Lymphoma
123 Epstein-Barr virus B cell, after
techniques undergoing clinical marrow transplant, Jan/Feb.
evaluation, May/June 121- 40-41
122 marrow transplant in, Jan/Feb.
radon and, Mar/Apr. 68-69 21-25
rb gene in, Mar/Apr. 72 results, Jan/Feb. 23
resection results in, May/June
115-117 M
screening for, Mar/Apr. 78-81
clinical trials, Mar/Apr. 79-80 Malignancy (see Cancer
smoking and, Mar/Apr. 68-69 Marrow transplant, Jan/Feb. 5—57
stage I abstract, Jan/Feb. 5
radiotherapy results in, May in breast cancer, Jan/Feb. 35-36
June 123 carboplatin in, Jan/Feb. 13
resection results in, May/June chemotherapy
115 intensive, role of, Jan/Feb. 6-9
stage Il single agent dose escalation,
radiotherapy results, May/June Jan/Feb. 8
123 complications, Jan/Feb. 37—44
resection results in, May/June cryopreservation in, Jan/Feb
115 10-11
stage Illa, resection results in, cyclophosphamide in, Jan/Feb.
May/June 116—117 12-13
stage IV, radiotherapy and che- cystitis after, hemorrhagic, Jan.
motherapy in, May/June 126 Feb. 44
staging, Mar/Apr. 86—92 cytomegalovirus after, Jan/Feb. 39
evaluation, Mar/Apr. 89-91 cytotoxic drugs in, Jan/Feb
techniques, Mar/Apr. 89-91 12-14
I'NM system, Mar/Apr. 87—88 endocrine dysfunction after, Jan.
stem cells in, pulmonary, Mar. Feb. 44
Apr. 84—85 engraftment
sulcus tumors, superior, May delay in, Jan/Feb. 43
June 123 effect of infections on, Jan/Feb.
surgery oi, May/June 112-118 40
with chen.otherapy, May/June future directions, Jan/Feb. 44—46
139-141 in hematological cancer, Jan/Feb.
failure patterns, May/June 117- 19-33
118 biological observations, Jan.
morbidity and n.9rtality of, Feb. 19-21
May/June 114-115 hematopoietic engraftment in,
procedures, May/June 113-114 Jan/Feb. 31
Curr Probl Cancer, November/December 1991
Marrow transplant (cont.) Morbidity in lung cancer
hematopoietic stem cell(s) with chemotherapy, May/June
graft, Jan/Feb. 9 134-135
storage, Jan/Feb. 9-11 radiotherapy, May/June 122
herpes simplex after, Jan/Feb. surgery, May/June 114-115
38-39 Mortality in lung cancer
high-dose therapy, principles of, with chemotherapy, May/June
Jan/Feb. 11-16 134-135
history, Jan/Feb. 5-9 surgery, May/June 114-115
in Hodgkin's disease, Jan/Feb. Mucin-glycoprotein epitopes: and
25-28 Lewis antigens, Nov/Dec. 321
results, Jan/Feb. 23, 28 Mutations (see Lung cancer, muta-
ifosfamide in, Jan/Feb. 13 tions in)
infections after, Jan/Feb. 37-41 Myeloma: Kaplan-Meier survival
in leukemia, Jan/Feb. 28—32 curves in, Nov/Dec. 336
liver toxicity after, Jan/Feb. 41-43
in lung cancer, small cell, Jan.
N
Feb. 33
in lymphoma, Jan/Feb. 21-25 Neuroblastoma: marrow transplant
results, Jan/Feb. 23 in, Jan/Feb. 33-34
lymphoma after, Epstein-Barr vi- Neuroendocrine features: of lung
rus B-cell, Jan/Feb. 40-41 cancer, Mar/Apr. 86
melphalan in, Jan/Feb. 13-14 Neuron specific enolase: as tumor
in neuroblastoma, Jan/Feb. marker, Nov/Dec. 329
33-34 Nicotine: in lung cancer, Mar/Apr.
in ovarian cancer, Jan/Feb. 36 72-73
purging in, Jan/Feb. 17-19
methods, Jan/Feb. 18
Oo
radiotherapy and, Jan/Feb. 14-16
rationale, Jan/Feb. 5-6 Oncogenes
in solid tumors, Jan/Feb. 33-36 in breast cancer, July/Aug. 178-
in testicular cancer, Jan/Feb. 34-35 181
thiotepa in, Jan/Feb. 13 in lung cancer (see Lung cancer,
toxicity in non-small cell, oncogenes in)
lung, Jan/Feb. 41 Oncology, tumor markers in (see
vascular, Jan/Feb. 43 Tumor markers in oncology)
Melphalan: in marrow transplant, Opioids: in lung cancer, Mar/Apr.
Jan/Feb. 13—14 72-73
‘=
Metastases Outcome: therapeutic, model of,
of breast cancer, July/Aug. 166-169 Jan/Feb. 12
cerebral metastasis, solitary, in Ovarian cancer: marrow transplant
lung cancer, May/June 117 in, Jan/Feb. 36
in esophageal cancer, sites, Sept.
Oct. 246 P
of gastric cancer, sites of, Sept
Oct. 247 Pancreas, cancer, CA 19-9 in, Nov.
of lung cancer (see Lung cancer, Dec. 325
metastases) Paraneoplastic syndromes: in non-
Model: of therapeutic outcome small cell lung cancer, Mar.
Jan/Feb. 12 Apr. 77
Curr Probl Cancer, Novermber/December 1991
Pericardial effusion: in lung cancer,
Mar/Apr. 76
p53 gene: abnormalities in lung Tamoxifen in breast cancer, July/
cancer, Mar/Apr. 72 Aug. 202—207, 210-211
Placental alkaline phosphatase: as trials, July/Aug. 203
tumor marker, Nov/Dec. Testicular cancer: marrow trans-
330—331 plant in, Jan/Feb. 34-35
Pleural effusion: malignant, in lung Therapeutic outcome: modei of,
cancer, Mar/Apr. 76 Jan/Feb. 12
Pregnancy: during breast cancer, Thiotepa: in marrow transplant,
July/Aug. 174-176 Jan/Feb. 13
Prostate Thoracic symptoms: in lung cancer,
acid phosphatase as tumor Mar/Apr. 75-77
marker, Nov/Dec. 328-329 Thyroglobulin: as tumor marker,
specific antigen as tumor marker, Nov/Dec. 331-333
Nov/Dec. 318-320 Tissue polypeptide antigen: as tu-
mor marker, Nov/Dec. 317
Toxicity
of chemotherapy in breast can-
Radiotherapy cer, July/Aug. 198-200
of esophageal carcinoma, Sept. of hormonal therapy in breast
Oct. 253 cancer, July/Aug. 211-213
with chemotherapy, Sept/Oct. liver, after marrow transplant,
263-266 Jan/Feb. 41-43
preoperative, Sept/Oct. 260-— lung, in marrow transplant, Jan.
261 Feb. 41
of lung cancer (see Lung cancer, vascular, after marrow transplant,
non-small cell, radiotherapy in) Jan/Feb. 43
marrow transplant and, Jan/Feb Transplantation, marrow (see Mar-
14-16 row transplant
Radon: and lung cancer, Mar/Apr. Tumoris)
68-69 germ cell, Nov/Dec. 316
ras mutations: in lung cancer, Mar. markers in oncology (see below)
Apr. 70 solid, marrow transplant in, Jan.
rb gene: in lung cancer, Mar/Apr. Feb. 33—36
72 Tumor markers in oncology, Nov.
Dec. 301—350
abstract, Nov/Dec. 301
Ss
alkaline phosphatase, placental,
Smoking: and lung cancer, Mar. Nov/Dec. 330-331
Apr. 68-69 alpha-fetoprotein, Nov/Dec. 313-
Solid tumors: marrow transplant in, 317
Jan/Feb. 33-36 beta-2-microglobulin, Nov/Dec.
Stem cells 335-338
hematopoietic (see Marrow trans- CA 15-3, Nov/Dec. 322
plant hematopoietic stem CA 19-9, Nov/Dec. 324-326
cell) CA 50, Nov/Dec. 324-326
of lung, in lung cancer, Mar/Apr. CA 125, Nov/Dec. 327-328
84-85 CA 195, Nov/Dec. 326-327
Stomach (see Gastric) calcitonin, Nov/Dec. 331
Curr Probl Cancer, November/December 1991
Tumor markers in oncology (cont.) lactic acid dehydrogenase, Nov.
cancer antigen, mucinous-like, Dec. 330
Nov/Dec. 323-324 major, summary of, Nov/Dec. 337
carcinoembryonic antigen, Nov. prostate specific antigen, Nov.
Dec. 304—313 Dec. 318-320
carcinoma antigen, squamous prostatic acid phosphatase, Nov.
cell, Nov/Dec. 318 Dec. 328-329
catecholamines, Nov/Dec. 333- thyroglobulin, Nov/Dec. 331-333
334 tissue polypeptide antigen, Nov.
classification of, Nov/Dec. 302- Dec. 317
303 use of, clinical, Nov/Dec. 301-350
DuPAN-2, Nov/Dec. 326
enolase, neuron-specific, Nov. V
Dec. 329
enzyme, Nov/Dec. 328-331 Vena cava syndrome: superior, in
following treatment course, Nov. lung cancer, Mar/Apr. 76
Dec. 338 Vessels: toxicity after marrow trans-
glycoprotein, Nov/Dec. 304—320 plant, Jan/Feb. 43
mucinous, Nov/Dec. 320-328 Viruses
gonadotropin, beta-human chori- cytomegalovirus after marrow
onic, Nov/Dec. 313-317 transplant, Jan/Feb. 39
hormones, Nov/Dec. 331-334 Epstein-Barr, B-cell lymphoma
immune system molecules, Nov after marrow transplant, Jan.
Dec. 334—338 Feb. 40-41
immunoglobulins, Nov/Dec. 334- herpes simplex after marrow
transplant, Jan/Feb. 38-39
335
STATEMENT OF OWMERSIOP
_ ==2*